according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 657612-00022
 Date of first issue: 02.05.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Alvimopan Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Piercetown

A86 HD21 Dunboyne, Ireland

Telephone : 908-740-4000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Additional Labelling

EUH210 Safety data sheet available on request.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 23. 28.09.2024 657612-00022 Date of first issue: 02.05.2016

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Componente			
Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Alvimopan	170098-38-1	Acute Tox. 4; H302	>= 1 - < 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : No special precautions are necessary for first aid responders.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

Version **Revision Date:** SDS Number: Date of last issue: 06.04.2024 28.09.2024 657612-00022 Date of first issue: 02.05.2016 2.3

> Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment:

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary. Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 23.09.2024 657612-00022 Date of first issue: 02.05.2016

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store in accordance with

the particular national regulations.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 657612-00022 Date of first issue: 02.05.2016

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dusts non-specific 4 mg/m3

Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable

dust)

Basis: IE OEL

10 mg/m3

Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable

dust)

Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Alvimopan	170098-38- 1	TWA	10 μg/m3	Internal
		Wipe limit	100 μg/100 cm ²	Internal

8.2 Exposure controls

Engineering measures

Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Eye/face protection : Wear the following personal protective equipment:

Safety goggles

Equipment should conform to I.S. EN 166

Hand protection

Material : Chemical-resistant gloves

Remarks : For prolonged or repeated contact use protective gloves.

Wash hands before breaks and at the end of workday.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 23. 28.09.2024 657612-00022 Date of first issue: 02.05.2016

Skin and body protection : Skin should be washed after contact.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 657612-00022
 Date of first issue: 02.05.2016

Partition coefficient: n-

octanol/water

: No data available

Vapour pressure : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

Date of last issue: 06.04.2024 Version **Revision Date:** SDS Number: 2.3 28.09.2024 657612-00022 Date of first issue: 02.05.2016

exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Components:

Alvimopan:

Acute oral toxicity : LD50 (Rat): > 500 mg/kg

LD50 (Mouse): > 4,000 mg/kg

Acute dermal toxicity LD50 (Mouse): > 2,000 mg/kg

Acute toxicity (other routes of :

LD50 (Rat): > 20 mg/kg

administration) Application Route: Intravenous

Remarks: No significant adverse effects were reported

Skin corrosion/irritation

Not classified based on available information.

Components:

Alvimopan:

Species Rabbit

Result Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Alvimopan:

Species Rabbit

Result Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Alvimopan:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 657612-00022
 Date of first issue: 02.05.2016

Test Type : Maximisation Test

Exposure routes : Dermal Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Alvimopan:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Mouse

Application Route: Oral

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Alvimopan:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 500 mg/kg body weight

Result : negative

Species : Mouse Application Route : Oral Exposure time : 2 Years

LOAEL : 4,000 mg/kg body weight

Result : positive Target Organs : Bone, Skin

Remarks : Benign and malignant tumor(s)

Adverse effects were observed in females only.

There is no evidence that these findings are relevant to hu-

mans.

Reproductive toxicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.3
 28.09.2024
 657612-00022
 Date of first issue: 02.05.2016

Components:

Alvimopan:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Intravenous injection Fertility: NOAEL: 5 mg/kg body weight

Result: No effects on fertility

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL: 200 mg/kg body weight

Result: No effects on fertility

Test Type: Fertility/early embryonic development

Species: Rabbit

Application Route: Intravenous

Fertility: NOAEL: 15 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 100 mg/kg body weight

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 200 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intravenous injection

Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: No significant adverse effects were reported

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intravenous injection

Developmental Toxicity: NOAEL: 15 mg/kg body weight Result: No significant adverse effects were reported

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 657612-00022 Date of first issue: 02.05.2016

Repeated dose toxicity

Components:

Alvimopan:

Species : Mouse
NOAEL : 1000 mg/kg
Application Route : Oral
Exposure time : 13 Weeks

Remarks : No significant adverse effects were reported

Species : Dog

NOAEL : 1000 mg/kg Application Route : Oral Exposure time : 39 Weeks

Remarks : No significant adverse effects were reported

Species : Rat

NOAEL : 500 mg/kg Application Route : Oral Exposure time : 1 yr

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 2 mg/kg
Application Route : Intravenous
Exposure time : 1 Months

Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

Alvimopan:

Ingestion : Symptoms: stomach discomfort, Gastrointestinal disturbance,

Nausea, Vomiting, Abdominal pain

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 23. 28.09.2024 657612-00022 Date of first issue: 02.05.2016

SECTION 12: Ecological information

12.1 Toxicity

Components:

Alvimopan:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 17 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 17 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

EC50 (Scenedesmus subspicatus): > 17 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Scenedesmus subspicatus): 17 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 920 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 920 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

12.2 Persistence and degradability

Components:

Alvimopan:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 4 % Exposure time: 28 d

12.3 Bioaccumulative potential

Components:

Alvimopan:

Partition coefficient: n- : log Pow: 0.52

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 23. 28.09.2024 657612-00022 Date of first issue: 02.05.2016

octanol/water

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.3 28.09.2024 657612-00022 Date of first issue: 02.05.2016

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Not applicable

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances,

mixtures and articles (Annex XVII)

REACH - Candidate List of Substances of Very High : Not applicable

Concern for Authorisation (Article 59).

Regulation (EC) on substances that deplete the ozone : Not applicable

layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia: Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 657612-00022 Date of first issue: 02.05.2016

ment and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H302 : Harmful if swallowed.

Full text of other abbreviations

Acute Tox. : Acute toxicity

IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occu-

pational Exposure Limit Values - Code of Practice, Schedule 1

and 2

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice: IARC - International Agency for Research on Cancer: IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test popula-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Alvimopan Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 657612-00022 Date of first issue: 02.05.2016

tion; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN